Clinical Trial Update: Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating glucagon response to prandial insulin in people with Type 1 diabetes has been terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperglycemia Postprandial
• Type 1 Diabetes Mellitus

Snippet

Sponsor: Washington University School of Medicine | Conditions: Type 1 Diabetes, Hyperglycemia, Postprandial | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-03-02